Rhizen’s discovery and development efforts are aimed at generating a new class of high-impact medicines. The company was established to serve as an IP resource, which can work on flexible business models with partners to commercialize these innovations. The company’s board of directors and management team carry decades of combined experience in the areas of pharmaceutical research, development and marketing across therapeutic areas and provide well devised goals to Rhizen to pursue its efforts with equal emphasis on innovation and collaboration.
Rhizen’s operations are highly focused and cost effective with well managed outsourcing of activities at globally recognized organizations while retaining core research through design and development. Rhizen’s efforts are complimented by richly experienced scientific advisory board bringing globally competent scientific edge. The combined efforts are aimed at commercial viability through filling the gaps in translational research. A significant scientific momentum was achieved within three years of incorporation by creating 6 preclinical leads out of which three are expected to reach to human clinical trials during 2012-2013 helping Rhizen to achieve critical valuation. A series of global patents have been applied to secure critical IP covering the leads and back-ups
Rhizen’s business efforts are well capitalized through private funding at this stage and the company intends to utilize revenue generated through out licensing to further advance its research pipeline